Multiparametric MRI in assessing the T-stage of prostate cancer: a multicentre study

Objective: To evaluate the possibilities and significance of preoperative multiparametric magnetic resonance imaging (mpMRI) in assessing the local staging of prostate cancer (PCa) versus postoperative pathomorphological examination. Materials and methods: The study included 83 men aged 54 to 87 years (median 66 years) with a verified diagnosis of prostate cancer. All patients underwent mpMRI of the pelvis prior to performing radical surgical treatment (radical prostatectomy-RP). The RP was performed no later than 2 weeks after the mpMRI. Results: Sensitivity, specificity, diagnostic accuracy, prediction of positive (PPV) and negative (NPV) results in the evaluation of extracapsular proliferation were: 89.5%, 90.6%, 91%, 88.0% and 92.3% respectively; in the evaluation of tumor invasion of seminal vesicles - 85.2%, 95.4%, 90%, 85.7% and 95.6%. Conclusion: The results of preoperative staging of patients with PCa through the use of mpMRI demonstrate high sensitivity, specificity and overall diagnostic accuracy, as well as high NPV and PPV. The introduction of extensive use of preoperative staging of patients with PCa by mpMRI can help to more personalize stratify groups of patients when choosing the tactics of radical treatment. The prescription of hormone therapy before the mpMRI can reduce the detectability of local advanced forms of PCa.

Рак предстательной железы, мультипараметрическая магнитно-резонансная томография, местнораспространенные формы рака предстательной железы, радикальная простатэктомия, prostate cancer, multiparametric, magnetic resonance imaging, locally advanced forms of prostate cancer, radical prostatectomy

1. Shukla-Dave A., Hricak H., Scardino P.T. Imaging low-risk prostate cancer. Current Opinion in Urology. 2008 г.;18(1):78-86.

2. Han M., Partin A.W., Zahurak M., Piantadosi S., Epstein J., Walsh P.C. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. Journal of Urology. 2003;169(2):517-23.

3. Walz J., Joniau S., Chun F.K., Isbarn H., Jeldres C., Yossepowitch O. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU International. 2011;107(5):765-70.

4. Swanson G.P., Basler J.W. Prognostic Factors for Failure after Prostatectomy. Journal of Cancer. 2011;2(6):1.

5. Мищенко А.В., Дубицкий Д.Л., Носов А.К. Основы использования магнитно резонансной томографии при раке предстательной железы. Лучевая диагностика и терапия. 2014;12-26.

6. Schröder F.H., Hermanek P., Denis L., Fair W.R., Gospodarowicz M.K., PavoneUMacaluso M. The TNM classification of prostate cancer. Prostate. 1992;21(4 S):129-38.

7. Weinreb J.C., Barentsz J.O., Choyke P.L., Cornud F., Haider M.A., Macura K.J., et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. European Urology. 2016;69(1):16-40.

8. Barentsz J.O., Weinreb J.C., Verma S., Thoeny H.C., Tempany C.M., Shtern F., et al. Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use. European Urology. 2016; 69(1):41-9.

9. Казымов А.Т., Исаев И.Г., Али-заде А.М., Гулиев Ф.А., Мусаев Т.Н., Алиев А.Р. Оценка степени местной распространенности рака предстательной железы по данным магнитно-резонансной томографии и клинических прогностических ф акторов. Онкоурология. 2015;11(2):55-60. https://doi. org/10.17650/1726-9776-2015-11-2-55-60

10. Kim C.K. Magnetic resonance imaging-guided prostate biopsy: Present and future. Korean Journal of Radiology. 2015;16(1):90-8.

11. Ахвердиева Г.И., Панов В.О., Тюрин И.Е., Долгушин Б.И., Матвеев В.Б., Камолов Б.Ш., Тарачкова Е.В., Булычкин П.В. Мультипараметрическая магнитно-резонансная томография в диагностике локального рецидива рака предстательной железы после радикальной простатэктомии. Онкоурология. 2015;11(4):72-80. https://doi.org/10.17650/1726-9776-2015-11-4-72-80

12. Коссов Ф.А., Камолов Б.Ш., Абдуллин И.И., Баранова Е.О., Шориков М.А., Панов В.О., Тюрин И.Е., Матвеев В.Б., Григорьев Н.А., Долгушин Б.И. Применение МРТ/УЗИ fusion-биопсии в диагностике клинически значимого рака предстательной железы. Онкоурология. 2017;13(3):61-70. https://doi. org/10.17650/1726-9776-2017-13-3-61-70

13. Kulldorff M. A spatial scan statistic. Communications Statistics - Theory Methods. 1997;26(6):1481-96.

14. Berger A.P., Gozzi C., Steiner H., Frauscher F., Varkarakis J., Rogatsch H., et al. Complication rate of transrectal ultrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores. The Journal of urology. 2004. с. 1478-80;

15. Fütterer J.J., Moche M., Busse H., YakarD. In-bore MR-guided biopsy systems and utility of PI-RADS. Topics in Magnetic Resonance Imaging. 2016;25(3):119-23.

16. Eiber M, Beer AJ, Holzapfel K, Tauber R, Ganter C, Weirich G, и др. Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol. 2010 г.;

17. Kapoor J., Namdarian B., Pedersen J., Hovens C., Moon D., Peters J., et al. Extraprostatic extension into periprostatic fat is a more important determinant of prostate cancer recurrence than an invasive phenotype. Journal of Urology. 2013;190(6):2061-6.

18. Russo J.K., Laszewski M., Rodacker M., Watkins P.L., Dufan T.A., Koleilat N., et al. Margin details matter: The prognostic significance of pseudocapsule invasion at the site of involved margin in prostatectomy specimens. Urologic Oncology: Seminars and Original Investigations. 2015;33(9):383.e1-383.e7.

19. Алексеев Б.Я., Крашенинников A.A., Нюшко К.М., Калпинский А.С., Каприн А.Д. Интермиттирующая гормональная терапия препаратом элигард у больных раком предстательной железы. Онкоурология. 2014;10(1):69-75. https://doi.org/10.17650/1726-9776-2014-10-1-69-75